MatchTx

Phase 3 clinical trials can cost more than $26,000 per patient and typically require over 1,000 patients to meet regulations and demonstrate statistically significant efficacy compared with placebo and alternatives.

MatchTx software and algorithms were designed to address several key client needs in utilizing clinical, genetic, and outcome data to make precise predictions about patients, samples, and oncology drugs.

Predict how well the patient will respond to a drug, or which treatment is best, based on characteristics and outcomes of the best matched cohorts.

Jeffrey Spitzner, PhD1; Trevor Allen, BA1; Guy Jacks, BA1;James L Chen, MD1,2 1MatchTX, LLC, Columbus, Ohio. 2Dept of Biomedical Informatics and Internal Medicine, The Ohio State University, Columbus, Ohio

K. Koehler, D. Liebner, and J. L. Chen are listed as authors.

MatchTx provides SaaS software that helps researchers, oncologists, and clinical trial managers identify biomarkers that predict cancer treatment outcomes. Its algorithms analyze genomic and clinical data to find Deep Genetic Signatures in reference datasets.

MatchTx develops healthcare analytics software to match patients with cancer drugs and clinical trials using genetic, clinical, and outcome data. Its technology was licensed exclusively from The Ohio State University, and it received a $125,000 grant from Ohio’s Third Frontier Program.

The company’s bioinformaticists developed algorithms to match novel treatments with patients most likely to respond positively.

Big Data healthcare analytics to match patients to the right oncology drugs/clinical trials.

Find the set of biomarkers that collectively predict treatment outcome for cancer patients